Padsevonil + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-Resistant Epilepsy
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Trial Timeline
Mar 6, 2019 → Sep 28, 2020
NCT ID
NCT03739840About Padsevonil + Placebo
Padsevonil + Placebo is a phase 3 stage product being developed by UCB for Drug-Resistant Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03739840. Target conditions include Drug-Resistant Epilepsy, Focal-Onset Seizures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03739840 | Phase 3 | Terminated |
Competing Products
6 competing products in Drug-Resistant Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OnabotulinumtoxinA 145 UNT [Botox] | AbbVie | Approved | 85 |
| Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid | Novartis | Phase 2 | 52 |
| UCB0942 | UCB | Phase 2 | 49 |
| Padsevonil | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |
| Padsevonil | UCB | Phase 2 | 49 |